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doi:10.1Objectives: In patients with chronic thromboembolic pulmonary hypertension, high flow in unobstructed lung
regions may induce small-vessel damage responsible for persistent pulmonary hypertension after pulmonary
thromboendarterectomy. In piglets, closure of an experimental aortopulmonary shunt reverses the flow-
induced vascular lesions and diminishes the elevated levels of messenger RNA (mRNA) expression for
endothelin-1 and endothelin receptor A (ETA). We wanted to study the effect of the ETA antagonist TBC
3711 on reversal of flow-induced pulmonary vascular lesions.
Methods: Twenty piglets were studied. In 15 piglets, pulmonary vasculopathy was induced by creating an aor-
topulmonary shunt. After 5 weeks of shunting, some animals were studied (n ¼ 5); others underwent shunt clo-
sure for 1 week with (n ¼ 5) or without (n ¼ 5) TBC3711 treatment. Anti-ETA treatment started 1 week before
and ended 1 week after the shunt closure. The controls were sham-operated animals (n ¼ 5).
Results:High blood flow led to medial hypertrophy of the distal pulmonary arteries (54.9% 1.3% vs 35.3%
0.9%; P< .0001) by stimulating smooth muscle cell proliferation (proliferating cell nuclear antigen) and in-
creased the expression of endothelin-1, ETA or endothelin receptor type A or endothelin receptor A, angiopoietin
1, and Tie2 (real-time polymerase chain reaction). One week after shunt closure, gene expression levels were nor-
mal and smooth muscle cells showed increased apoptosis (terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling) without proliferation. However, pulmonary artery wall thickness returned to control values
only in the group given TBC3711 (33.2%  8% with and 50.3%  1.3% without; P< .05).
Conclusions: Anti-ETA therapy accelerated the reversal of flow-induced pulmonary arterial disease after flow
correction. In patients with chronic thromboembolic pulmonary hypertension and severe distal pulmonary vas-
culopathy, anti-ETA agents may prove useful for preventing persistent pulmonary hypertension after pulmonary
thromboendarterectomy. (J Thorac Cardiovasc Surg 2010;140:677-83)E
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SChronic thromboembolic pulmonary hypertension (CTEPH)
is due to partial obstruction of the pulmonary arterial tree by
organized clots, which increase the pulmonary vascular resis-
tance (PVR), leading to progressive pulmonary hypertension
(PH) and right heart failure.1 The main treatment is pulmo-
nary thromboendarterectomy (PTE), which provides long-
term hemodynamic and functional benefits and increases
life expectancy.2-5 However, PTE is associated with a 10%
mortality rate related chiefly to persistent PH despite
removal of the thrombotic material.2-4 Persistent PH may
reflect the existence of lesions in small precapillary vessels
that are not accessible to surgery.6 Histopathologic studies
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The Journal of Thoracic and Capathic PH and Eisenmenger syndrome.7-9 These distal
lesions in the unobstructed territories may contribute to the
progression of the hemodynamic abnormalities and
symptoms in the absence of further pulmonary embolism.10,11
Compared with acute pulmonary embolism, CTEPH with
a similar degree of vascular obstruction is associated with far
higher PVR values as assessed by lung perfusion scanning.8
In patients with CTEPH, the unobstructed territories are
chronically exposed to high blood flow owing to cardiac out-
put redistribution.10,12 This high blood flow may contribute
to increase the PVR,13 inasmuch as chronic high flow causes
distal arteriopathy with vascular remodeling7,14 similar to
that found in primary PH.15-19 As a result, alterations
develop in the distal pulmonary arteries, adding to the
PVR increase induced by the proximal occlusion. Greater
severity of the microvascular disease is associated with
higher PVR values, which in turn predict higher mortality
after PTE.6 We have developed a piglet model of pulmonary
vasculopathy induced by high blood flow to the lungs
through an aortopulmonary shunt left open for 5 weeks.
There was no chronic pulmonary artery obstruction in our
model, which therefore does not provide any information
about potential effects of chronically occluded territories
on nonoccluded territories. However, our model replicatesrdiovascular Surgery c Volume 140, Number 3 677
Abbreviations and Acronyms
Ang-1 ¼ angiopoietin-1
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
ET-1 ¼ endothelin-1
ETA ¼ endothelin receptor type A
ETB ¼ endothelin receptor type B
mRNA ¼ messenger RNA
PA-SMC ¼ pulmonary artery smooth muscle cell
PCNA ¼ proliferating cell nuclear antigen
PH ¼ pulmonary hypertension
PTE ¼ pulmonary thromboendarterectomie
PVR ¼ pulmonary vascular resistance
RT-PCR ¼ real-time polymerase chain reaction
TUNEL ¼ terminal deoxynucleotidyl transferase–
mediated dUTP nick
end labeling
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Sthe functional vascular changes seen in the nonoccluded ter-
ritories of patients with CTEPH.20 We21 previously reported
that the shunt induced thickening of the media of small pul-
monary arteries (<200 mm in diameter) and overexpression
of endothelin-1 (ET-1), endothelin receptor type A (ETA),
angiopoietin-1 (Ang-1), and Tie2. One week after shunt clo-
sure, we found normal expression of mRNAs for ET-1,
ETA, Ang-1, and Tie2 and partial reversal of the medial hy-
pertrophy.21 These data suggest that ET-1 and ETA may
hold promise as therapeutic targets in patients with severe
distal microvascular disease in unobstructed territories.
Treatments targeting ET-1 have been used in other forms
of PH. However, there is no evidence that ET-1 antagonist
treatment given before PTE improves postoperative out-
comes in patients with severe distal vascular changes.
The objective of this study was to evaluate the effects of
the selective ETA antagonist TBC3711 on reversal of
flow-induced pulmonary vasculopathy after shunt closure
in our piglet model.MATERIALS AND METHODS
We studied 20 Large White piglets weighing 21 3 kg. The study com-
plied with the National Institutes of Health ‘‘Guidelines for the Care and
Use of Laboratory Animals’’ and was approved by the institutional commit-
tee on animal welfare.
Experimental Design
Twenty piglets were randomly allocated to 4 groups of 5. An aortopul-
monary shunt was created in 3 groups to increase the blood flow to the
pulmonary arteries. After 5 weeks of shunting, the animals in 1 of these
groups were humanely killed (high-flow group) and those in the other 2
groups underwent shunt closure and thenwere humanely killed 1week later.
Of these 2 shunt-closure groups, 1 was untreated and killed 1 week after
shunt closure (flow-correction group) and the other was treated with the se-
lective ETA antagonist TBC3711 (flow-correction plus anti-ETA group),678 The Journal of Thoracic and Cardiovascular Surgwhich was started 1 week before shunt closure and continued until 1
week after shunt closure, when the animals were killed. The animals in
the fourth group were killed 5 weeks after a sham operation consisting in
dissection of the pulmonary artery (sham group).
Previous in vitro studies in humans and piglets have established that
TBC3711 is a selective ETA antagonist.22,23 We used TBC3711 capsules
in 2 daily oral doses of 11 mg $ kg1 for 2 weeks.23
Surgical Procedures
An aortopulmonary shunt was created and closed as previously
described.21
Hemodynamic measurements and lung harvesting. Pul-
monary hemodynamic variables, aortic blood flow, pressures, and blood
gases were measured as previously described.21
Biopsy specimens weighing 300 to 500 mg were taken from the left up-
per lobe, snap-frozen in liquid nitrogen, and stored at –70C or fixed in 4%
paraformaldehyde solution.
Light microscopy and morphometry. Fixed lung sections
were processed by standard histologic techniques and embedded in paraffin.
We sought to identify 30 to 40 arteries measuring less than 200 mm in diam-
eter in the lung specimens from each piglet. Media thickness (MT) was
calculated as follows:%MT¼ (EDID/ED) $ 100, where ED is the exter-
nal diameter and ID the internal diameter.
In situ evaluation of smooth muscle cell death and
proliferation and of collagen accumulation. We evaluated
the proliferation of pulmonary artery smooth muscle cells (PA-SMCs) by
labeling the proliferating cell nuclear antigen (PCNA).21 Cells undergoing
apoptosis were detected with the ApopTag Red In Situ Apoptosis Detection
Kit (Qbiogene, Illkirch, France). To assess collagen accumulation, we
deparaffinized paraffin-embedded sections and stained them with Masson
trichrome stain.
Real-time quantification by polymerase chain reaction
assay (RT-PCR). RT-PCR assays were conducted as previously
described.16 The primers for ET-1, ETA, and endothelin receptor type B
(ETB) were the specific porcine primers previously described by Rondelet
and associates.16 For Ang-1, Tie2, and 18S RNA, we used primers designed
on Primer Express software (Applied Biosystems, Foster City, Calif).
Statistical Analysis
All results are reported as means  standard error of the mean. The
Kolmogorov–Smirnov test was used on each variable to determine whether
the values were normally distributed. One-way analysis of covariance was
performed using the weight of the piglets as the covariate, followed by
Fisher’s test for between-group comparisons. All statistical analyses were
performed with Statview IV software (Abacus Concept, Berkeley, Calif).RESULTS
The animals in the 2 flow-correction groups were kept 1
week longer than the animals in the high-flow and sham
groups and, accordingly, exhibited higher mean weights
when humanely killed (34  5 kg and 40  8 kg in the
flow-correction groups with and without anti-ETA treatment,
respectively, and 25  3 kg and 27  4 kg in the high-flow
and sham groups, respectively).
Effect of the Aortopulmonary Shunt on
Hemodynamic Variables
Compared with the sham-operated animals, animals in the
high-flow group had higher values for cardiac output (3.4 
0.4 L/min vs 2.1  0.16 L/min) and mean pulmonary arteryery c September 2010
TABLE 1. Changes in hemodynamic variables
Sham High flow Flow correction Flow correctionþanti-ETA
Weight (kg) 25  3 27  4 41  7 34  5
HR (beats/min) 95  5 90  2 90  8 90  16
Q (L/min) 2.1  0.16 3.4  0.4* 2.2  0.6y 1.67  0.2y
Indexed Q (mL $min1 $ kg1) 90  26 118  36* 45  10z 49  14z
mSAP (mm Hg) 56  2 52  4 50  4 47.4  6
mPAP (mm Hg) 10.2  0.5 15.9  1.2* 10.1  2y 9  3y
ETA, endothelin receptor type A; HR, heart rate; Q, cardiac output; mSAP, mean systemic arterial pressure; mPAP, mean pulmonary arterial pressure. *P< .05 vs sham group.
yP< .05 vs high-flow group. zP< .05 vs sham and high-flow groups.
Mercier et al Evolving Technology/Basic Sciencepressure (15.9 1.2 mm Hg vs 10.2 0.5 mm Hg; P<.05)
(Table 1). In both flow-corrected groups, cardiac output and
mean pulmonary artery pressure were similar and returned to
sham values. Heart rate and mean systemic arterial pressure
were similar in all groups.
Pulmonary Vascular Remodeling
Five weeks after shunt creation (high-flow group), media
thickness of pulmonary arteries less than 200 mm in diameter
was significantly greater than in the sham group (54.9% 
1.3% vs 35.3%  0.9%; P< .001). One week after shunt
closure alone (flow-correction group), media thickness was
nonsignificantly decreased compared with the high-flow
group (50.3%  1.3% vs 54.9%  1.3%; P ¼ .062).
When anti-ETA treatment was given, media thickness 1
week after shunt closure was not significantly different
from the value in the sham group (33.2%  8% vs 35.3%p=NS 
0.2 
0. 3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
%
M
T
=
(
E
D
-
I
D
)
/
E
D
Sham Shunt-open 1 wk Shunt-
closed
1 wk Shunt-
Closed
+ anti ETA
p<0.05 
p<0.05 
1 
FIGURE 1. Box plot of the percentage of media thickness of small pulmo-
nary arteries (<200 mm) assessed bymorphometry (3400) in the sham group
(35.5%  0.9%), high-flow group (54.9%  1.3%), flow-correction group
(50.3%  1.3%), and flow-correction plus anti-ETA group (33.2% 
8%). Media thickness returned to sham values 1 week after shunt closure in
the group given anti-ETA therapy.MT,Media thickness; ED, external diam-
eter; ID, internal diameter.
The Journal of Thoracic and Ca
E
T
/B
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shunt closure, media thickness had decreased significantly
more in animals that received anti-ETA treatment (P¼ .001).
PCNA labeling showed PA-SMC proliferation in the dis-
tal arteries in the high-flow group (22.6%  14% vs 6.4%
 9% in the sham group; P< .05), with a return to sham
values 1 week after shunt closure. Conversely, the number
of apoptotic cells detected by terminal deoxynucleotidyl
transferase–mediated dUTP nick end labeling (TUNEL) in
pulmonary arterial walls was not significantly different
between the high-flow group and the sham group (6.9% 
5% vs 9.4%  10%; P ¼ not significant) but was signifi-
cantly higher in the flow-correction group than in the sham
group (23.2%  16% vs 9.4%  10%; P< .05). Flow-
correction plus anti-ETA treatment was associated with
decreased PA-SMC proliferation (5.9%  6% vs 22.6%
 14% PCNA-positive cells; P< .05) and with an increase
in apoptotic PA-SMCs (17.7%  9% vs 9.4%  10%;
P< .05). PCNA and TUNEL labeling were similar in both
flow-correction groups. Collagen accumulation around the
pulmonary arteries was not different across groups
(Figures 2 and 3).
Expression of Genes Involved in the ET-1 and Ang-1
Pathways (Figures 4 and 5)
Compared with the sham group, the high-flow group had
higher mRNA levels for ET-1, ETA, Ang-1, and Tie2; there
was no difference for steady-state ETB mRNA.
ETA, Ang-1, and Tie 2 mRNA levels were not signifi-
cantly different from the sham values in either of the flow-
correction groups. ET-1 expression in the flow-correction
group was also similar to the sham value. In the flow-
correction plus anti-ETA group, ET-1 expression was lower
than in the high-flow group but higher than in the sham group.
DISCUSSION
In a model of flow-induced pulmonary vasculopathy in-
duced by 5 weeks of aortopulmonary shunting, the distal arte-
rial medial hypertrophy resulting from smooth muscle cell
proliferation and the overexpression of ET-1, ETA, Ang-1,
and Tie2 in the lung parenchyma showed greater improve-
ments 1 week after shunt closure in the animals given a selec-
tive ETA antagonist for 2weeks than in the untreated animals.rdiovascular Surgery c Volume 140, Number 3 679
FIGURE 2. Evaluation of in situ proliferation of pulmonary artery smooth muscle cells (PA-SMCs) by PCNA labeling (A, B, C, D) of PA-SMC death by
TUNEL (E, F, G, H) and of collagen accumulation by Masson trichrome staining (I, J, K, L) in the high-flow, flow-correction, flow-correction plus anti-ETA,
and sham groups (3400). Positive cells by TUNEL and PCNA labeling are brown. Collagen is stained blue by Masson’s trichrome. Pulmonary artery medial
hypertrophy in the high-flow group is related to PA-SMC proliferation (B, arrow) without intravascular collagen accumulation (J). The decrease in media
thickness 1 week after shunt closure alone or with anti-ETA was associated with a decrease in PCNA-positive cells (C, D) and with an increase in
TUNEL-positive cells (G, H, asterisk). Anti-ETA therapy was started 1 week before shunt closure and the smaller media thickness value in the group given
anti-ETA indicates that the treatment was effective in diminishing the medial hypertrophy. TUNEL, Terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling; ETA, endothelin receptor type A; PCNA, proliferating cell nuclear antigen.
Evolving Technology/Basic Science Mercier et al
E
T
/B
SThis finding supports a key role for ET-1 and ETA in the de-
velopment of flow-induced pulmonary vasculopathy.
After pulmonary embolism, the unobstructed lung territory
is exposed to chronic high blood flow owing to redistribution
of the cardiac output.10,12 In patients with severe CTEPH
(defined as very high PVR), extensive distal pulmonary
lesions induced by high blood flow may result in failure of
PTE to lower the PVR and, therefore, in increased680 The Journal of Thoracic and Cardiovascular Surgpostoperative morbidity and mortality rates.10,12,13 In our
animal model,21 5 weeks of aortopulmonary shunting led
to hypertrophy of the distal arterial media related to smooth
muscle cell proliferation, as shown by PCNA labeling. We
found that the flow-induced distal vasculopathy was associ-
ated with overexpression of mRNAs for ET-1, ETA, Ang-
1, and Tie2. When we used shunt closure to replicate the
effects of PTE on nonoccluded territories, we found thatery c September 2010
FIGURE 3. Percentage of PCNA and TUNEL-positive cells in the distal pulmonary artery wall in all groups of piglets. PA-SMC proliferation was noted in
the high-flow group but was no longer present 1 week after shunt closure. PA-SMC apoptosis was increased 1 week after shunt closure with or without anti-
ETA therapy. TUNEL, Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling; ETA, endothelin receptor type A; PCNA, proliferating cell
nuclear antigen. P< .05 vs sham.
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ETA, Ang-1, and Tie 2 returned to sham values within 1
week. Reversal of the vasculopathy was associated with a de-
crease in PA-SMC proliferation and with an increase in PA-
SMC apoptosis. In an earlier study, we21 examined piglets 5
weeks after shunt closure and found a marked improvement
in the distal vascular alterations with no change in the ET-1
pathway but with overexpression of ETB mRNA. We sug-
gested that, in our model, ETB might be involved in control-
ling ET-1 clearance and, consequently, might contribute to
reversal of the flow-induced vasculopathy. This study21
showed that increased expression of ET-1 mRNA was asso-
ciated with the development of distal pulmonary vasculop-
athy. Indeed, among endogenous vasoconstrictors, ET-1
has one of the strongest and longest lasting effects. Further-
more, ET-1 has been shown to play a pathogenic role in
idiopathic PH, which is characterized by distal vascular
lesions similar to those induced by high blood flow. We
therefore investigated the effect of an ET-1 receptor antago-
nist on reversal of flow-induced vasculopathy after flow
correction. We21 studied a selective ETA antagonist because
of the possible beneficial role of the ETB receptor on reversal
of flow-induced distal vasculopathy.
Administration of an ETA antagonist exerted a substantial
effect on reversal of the flow-induced distal vasculopathy af-
ter flow correction. One week after shunt closure, reversal of
the medial hypertrophy of distal arteries was complete in the
group given the ETA antagonist and incomplete in the un-
treated group. In both groups, reversal of the medial hyper-
trophy after flow correction was due to decreased PA-SMC
proliferation and increased PA-SMC apoptosis. Thus,
medial hypertrophy reversal after flow correction was accel-
erated by treatment with a selective ETA antagonist.
One week after the shunt closure, normalization of ET-1,
ETA, Ang-1, and Tie2 mRNA expressions preceded the nor-
malization of media thickness. This result is consistent withThe Journal of Thoracic and Cathe key role of ET-1 and Ang-1 in distal pulmonary remod-
eling. ET-1 expression analysis in the group given anti-ETA
therapy could be not strictly accurate inasmuch as ET-1 is
the therapeutic target. Therefore, we hypothesized that the
higher level of ET-1 expression in the group given anti-
ETA therapy could be related to a negative feedback effect.
Over the past decade, several targeted treatments have been
used in patients with PH, including prostacyclin analogs,
endothelin-receptor antagonists, and phosphodiesterase-5 in-
hibitors. Marked structural changes in nonoccluded pulmo-
nary arteries have been reported in CTEPH,7 and these
targeted treatments have been used in patients with inoperable
CTEPH. As mortality after pulmonary endarterectomy is
increased in patients with high preoperative and postoperative
PVR, such treatments are also strongly recommended preop-
eratively in patients with severe CTEPH. Data on the efficacy
of endothelin-receptor antagonist therapy in CTEPH are
limited and come mainly from nonrandomized trials. Many
studies24-27 found encouraging results with the ETA/ETB
antagonist bosentan in patients with inoperable CTEPH or
persistent PH after PTE. Right heart catheterization values,
functional status and tests, and pro–brain natriuretic peptide
levels improved significantly with bosentan treatment. In
a multicenter randomized trial comprising a 4-month
parallel-group comparison of bosentan with a placebo, bosen-
tan therapy significantly improved PVR and cardiac index
values.28 A study of patients with inoperable CTEPH diag-
nosed in 2003 or later, that is, after the introduction of targeted
therapies, showedan82% survival after 1 year and a 70% sur-
vival after 3 years.5 Nevertheless, long-term survival is best
with PTE, which therefore remains the treatment of choice.5
These findings are consistent with a key role for distal pulmo-
nary vasculopathy in patients with CTEPH and therefore with
amajor place for treatments targeting the endothelin receptors.
Conceivably, endothelin-receptor antagonist therapy
might prove useful as a bridge to PTE in patients whordiovascular Surgery c Volume 140, Number 3 681
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FIGURE 4. Quantification by RT-PCR of the mRNAs for endothelin-1
(ET-1) and its receptors (ETA and ETB) in lung parenchyma. High blood
flow in the lungs increased the expression of ET-1 and ETA mRNAs but
did not change the steady-state level of ETB mRNA expression. One
week after shunt closure, ET-1 and ETA mRNA levels had returned to nor-
mal. Except for ET-1, mRNA levels decreased similarly after flow correc-
tion with and without anti-ETA therapy. The ET-1 level remained
elevated in the anti-ETA group. *P< .05 vs sham. **P< .05 vs 1 week
shunt-closed.
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FIGURE 5. Quantification of angiopoietin-1 (Ang-1) and Tie 2 mRNA
levels in lung parenchyma from the sham, high-flow, flow-correction, and
flow-correction plus anti-ETA groups. High blood flow in the lungs in-
creased the expression of angiopoietin-1 and Tie2 mRNAs. Shunt closure
with or without anti-ETA reversed the overexpression of these genes.
ETA, Endothelin receptor type A.
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Shave a high operative risk with very high PVR values (>900
dyn $ s $ cm5) and moderate proximal artery occlusion as
assessed by pulmonary angiography and thoracic computed
tomography. A discrepancy between high PVR values and
limited proximal occlusion is indirect evidence of major
damage to the distal nonoccluded arterial bed. Our findings
suggest that endothelin receptor antagonist therapy started
before PTE in patients with high-risk CTEPH may acceler-
ate the postoperative reversal of the flow-induced vasculop-
athy, thereby decreasing postoperative mortality.CONCLUSION
ET-1 and its receptor ETA play a key role in the develop-
ment of flow-induced pulmonary vasculopathy in the nonoc-
cluded pulmonary arterial bed of patients with CTEPH.
Flow correction by aortopulmonary shunt closure to repli-
cate the effects of PTE in patients with CTEPHwas followed
by rapid normalization of ET-1 expression and incomplete682 The Journal of Thoracic and Cardiovascular Surgreversal of distal artery medial hypertrophy. When the selec-
tive ETA antagonist TBC3711 was used in addition to flow
correction, reversal of the flow-induced alterations was
accelerated. This ETA antagonist may hold promise for
improving post-PTE outcomes in patients with CTEPH
who have high PVR values, most notably those with moder-
ate proximal occlusion.
We are grateful to Encysive Pharmaceuticals for donating the
TBC3711 used in this study.References
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